Showing 281-290 of 7686 results for "".
Pearls for Managing Rosacea During Home Isolation
https://practicaldermatology.com/topics/acne-rosacea/pearls-for-managing-rosacea-during-home-isolation/23279/Encourage patients to keep up with skincare and prescription regimens and be prepared to offer in-office procedures when appropriate.The Importance of the Atopic Dermatitis Pipeline
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37148/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, provides an overview of important research underway involving new therapeutics for the treatment of atopJAK Inhibitors in Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/jak-inhibitors-vitiligo-treatment/24559/Dr. Ted Lain, a dermatologist practicing in Austin, Texas, talks with Practical Dermatology about the latest developments and the promise of Janus kinase (JAK) inhibitors for the treatment of vitiligo. Dr. Lain covers the current impact of JAK inhibitors, their mechanism of action, how he's using thDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thAn Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thFinally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."DermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PAll About Innovations at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/all-about-innovations-at-derm2021/19965/Whether you’re a new or experienced learner in the dermatology PA/NP space, Sandri Johnson, FNP-BC, says the DERM2021 NP/PA CME Conference has something to offer. Attendees will learn about the latest innovations in the field.The Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.